Dose escalation schedule (revision 11)
Old revision·20:08, 13 Feb 2025·PreregPriya
| Dose escalation scheduleDosing practice | |
|---|---|
Stepwise increases held long enough for tolerance to develop at each level. | |
| Purpose | Tolerability, not efficacy |
| Typical step interval | 4 weeks for weekly agents |
| Limiting effect | Gastrointestinal adverse events |
| Topic infobox · conventions | |
A dose escalation schedule is a planned stepwise increase from a starting dose to a maintenance dose. For incretin agonists it exists to manage tolerability: the starting dose is generally below the effective range, and its purpose is to allow gastrointestinal adaptation before an effective dose is reached.[1]
Step intervals for weekly agents are conventionally four weeks, which is approximately the time to steady state for a peptide with a half-life of several days. Escalating faster raises the dose before the previous step is fully expressed, so both exposure and adverse effects accumulate.[2]
Compressing an escalation predictably increases gastrointestinal adverse events and discontinuation. This is one of the better-characterised relationships in the field, since the escalation schedules used in trials were themselves selected on tolerability grounds.[3]
Why escalation works
[edit]Nausea and vomiting from incretin agonism attenuate with continued exposure at a constant dose, an adaptation associated with the attenuation of the delay in gastric emptying over the same period. Escalation exploits that adaptation by holding each dose long enough for it to occur before increasing.[1]
The insulinotropic and appetite effects do not attenuate in the same way, so the adaptation is selective: tolerability improves while efficacy is retained. This asymmetry is what makes the strategy work at all.
The four-week step interval matches the pharmacokinetics. With a half-life of about seven days, steady state is reached in four to five weeks, so a step held for four weeks is assessed at close to its full expression. A shorter step assesses a dose whose effect is still increasing.[2]
Representative schedules
[edit]| Product class | Starting dose | Steps | Interval |
|---|---|---|---|
| Weekly Semaglutide, obesity | 0.25 mg | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg | 4 weeks |
| Weekly Tirzepatide | 2.5 mg | 2.5 → 5 → 10 → 15 mg | 4 weeks |
| Daily Liraglutide, obesity | 0.6 mg | 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg | 1 week |
Daily agents escalate weekly rather than monthly, for the same pharmacokinetic reason in reverse: steady state is reached in days, so a week is ample. The number of steps is similar; the calendar time is very different.[3]
References
- ^ a b Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
- ^ a b Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." Frontiers in Endocrinology 10:155 (2019). PMID 31031702.
- ^ a b Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine 384(11):989–1002 (2021). PMID 33567185.